AzTrials
AzTrials

AgingNCT06501547

Association of Leucocyte Telomere Length With DPAS Score in Skin Aging

An observational study of Aging and Skin Laxity, run by Dr.dr.Irma Bernadette, SpKK (K) at 3 sites in Indonesia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal is to know the profile of photoaging based on clinical examination, Dermoscopic Photoaging Scale and leucocyte telomere length The main questions of Research are: what is the profile of photoaging based on clinical examination results in skin aging what is the profile of photoaging based on DPAS Score in skin… Read more about this study

Who is it for?
Ages 29 to 61 yearsHealthy volunteers can take part
Conditions the study is for
Aging, Skin Laxity
What is being tested?
Leucocyte Telomere Length from blood draw
How many people
20 participants
Where
3 sitesIndonesia
Study dates
1 Oct 2023to 1 Sep 2024
How long will I take part?
1 Day
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 29 to 61 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Study population: The study population consisted of eligible male and female participants within the prespecified age ranges who provided written informed consent. Participants were excluded if they were pregnant or breastfeeding or had a history of relevant diseases or genetic disorders. All participants provided written informed consent for participation in the study.

Who may be able to join

  • Female and Male (age 29-31 years old and 59-61 years old
  • signs of aging

Who cannot join

  • pregnant or breastfeeding
  • have disease or genetic problem

Trial locations and contacts

3 sites in 1 country.

Indonesia3 sites
  • Department of Dermatology and Venereology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital

    Jakarta Pusat, DKI Jakarta, 10430

  • Department of Dermatology and Venereology, Faculty of Medicine, University of Sam Ratulangi, Prof. RD Kandou Central General Hospital

    Manado, North Sulawesi, 95115

  • Department of Dermatology and Venereology, Faculty of Medicine, Universitas Andalas, Dr. M Djamil Central General Hospital

    Padang, West Sumatra, 25171

Other trials in Indonesia

About this study

Official title: Association of Leucocyte Telomere Length With Clinical Examination and Dermoscopic Photoaging Scale (DPAS) Score in Skin Aging: a Pilot Study

The goal is to know the profile of photoaging based on clinical examination, Dermoscopic Photoaging Scale and leucocyte telomere length

The main questions of Research are:

Read more
  • what is the profile of photoaging based on clinical examination results in skin aging
  • what is the profile of photoaging based on DPAS Score in skin aging
  • what is the profile of leucocyte telomere length in skin aging

Participants are female and male with the age of 29-31 years old and 59-61 years old. They will be examined by dermatovenereologist and will be photographed in 5 positions, they will get dermocopy on forehead, right cheek , left cheek, and chin, and their blood will be drawn about 10 mL in order to get the profile of leucocyte telomere length

Read the detailed description

Skin aging is a process of deterioration in the physiological structure and function of the skin that significantly increases in the 4th and 5th decades of life. Skin aging is a combination of physiological and pathological aging. Physiological change cannot be avoided and mandatory for everyone, pathological aging ir extrinsic aging is an abnormal skin condition caused by cigarettes, pollution and ultraviolet (UV). In general, the clinical characteristics of skin aging consist of pigmentation changes, hydration disorders, the appearance of wrinkles and skin tumors. The photoaging assessment was first proposed in 1996 by Dr. Richard Glogau, The Glogau scale assesses photoaging based on clinical assessment grouped into 4 categories, namely types I, II, III, and IV,where each type is graded by the severity of wrinkles, namely from mild, moderate, advanced, and severe. Isik et al. developed an instrument for quantitative skin aging assessment using dermoscopy. This examination is non-invasive and is expected to provide a more objective assessment. There are four facial regions assessed in the DPAS score calculation: forehead, right cheek, left cheek, and chin. The sum of the scores of the four regions is assessed based on 11 parameters, with a maximum final score of 44. Telomeres are repetitive DNA-Protein complexes located at the ends of chromosomes of eukarotic cells, and their function is to maintain chromosome stability during cell division, by protecting chromosomes from degradation and fusion. Many factors affect telomere length, such as body mass index, hormonal therapy, antioxidant intake, chronic diseases, and gender. Research by son et al. found that telomere length shortening was validated to increase the odds of skin aging (OR=0.96, 95% CI: 0.9332-0.99566, P= 0.03) Telomeres are closely linked to cellular aging, especially in dermal cells and telomere shortening in skin fibroblasts may lead to epidermal aging and barrier function defectcs.

Conditions
Aging, Skin Laxity
Being tested
Leucocyte Telomere Length from blood draw
Keywords
Dermoscopy, Dermoscopic photoaging scale (DPAS), Glogau scale, Leucocyte telomere length (LTL), Photoaging, Skin aging, Telomere, Ultraviolet (UV)
Medical subject headings
Cutis Laxa

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Leucocyte Telomere Length from blood drawGenetic

    blood draw, PCR method to see leucocyte telomere length

Study groups in NCT06501547
Study groupRoleWhat they receive
lifestyle counselingpatient will be asked about the mean of sun exposure per week
Receives: Genetic: Leucocyte Telomere Length from blood draw
Clinical examinationpatients's face were assessed by the doctor by using Glogau scale and the doctor will perform dermoscopic tes to assess dermoscopic photoaging scale (DPAS) score to obtain the score of skin aging
Receives: Genetic: Leucocyte Telomere Length from blood draw

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. profile of leucocyte telomere length

    profile of leucocyte telomere length in skin aging

    Measured: 1 year

  2. Profile of skin examination from Glogau scale

    Glogau type 1 (mild) is without wrinkles (Age of 28-35 years), type II (moderate) is wrinkles in motion (age of 35-50 years), III (advanced) with wrinkles at rest (age of 50-65 years), type IV (severe) is wrinkles all over the face (age of 60-75)

    Measured: 1 year

  3. profile of skin examination with dermoscopic photoaging scale (DPAS)

    skin aging is assessed from dermoscopic photoaging scale on dermoscopic images, looking at pigmentary changes, vascular changes, telangiectasis, wrinkles, actinic keratoses, and blackheads. There are four facial regions assessed in the DPAS score calculation, namely the forehead, right cheek, left cheek, and chin. The sum of the scores of the four regions is assessed based on 11 parameters, with a maximum final score of 44.

    The greater the score, the higher marks of skin aging

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Jul 2024
  2. Study start1 Oct 2023
  3. Primary completion30 Apr 2024
  4. Study completion1 Sep 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Ecologic or community
Time perspective
Cross-sectional
Enrolment
20 participants (actual)
Target duration
1 Day
IDs, dates and publications
ClinicalTrials.gov ID
NCT06501547
Sponsor's protocol ID
tes
Status last verified
Jul 2024
First submitted
2 Jun 2024
Last updated
30 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: provide positive impact for Cipto Mangunkusumo National Hospital and worldwide

Questions about this trial

What is this clinical trial studying?

An observational study of Aging and Skin Laxity, run by Dr.dr.Irma Bernadette, SpKK (K) at 3 sites in Indonesia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in Indonesia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

profile of leucocyte telomere length (time frame: 1 year). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in